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In this study, we have investigated the role of endoglin (CD105), a regulator of transforming growth factor (TGF)-b1 signalling on
endothelial cells, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor-A (VEGF-A) in cervical cancer.
We have measured the number and determined the location of both newly formed (CD105-positive) and the overall number of
(CD31-positive) blood vessels, and bFGF and VEGF-A expression using immunohistochemistry in 30 cervical carcinoma specimens.
Vascular endothelial growth factor-A mRNA expression was determined using RNA-in situ hybridisation. CD105- and CD31-positive
vessels and bFGF- and VEGF-A-positive cells were predominantly present in the stroma. The presence of CD105- and
CD31-positive vessels in the stroma did neither correlate with the number of VEGF-A-positive cells nor the number of bFGF-positive
cells. However, the number of CD105- and CD31-positive vessels was associated with the expression of VEGF-A mRNA in the
epithelial cell clusters (P¼0.013 and P¼0.005, respectively). The presence of CD105-positive and CD31-positive vessels was
associated with the expression of avb6 (a TGF-b1 activator; P¼0.013 and P¼0.006, respectively). Clinically, the number of CD105-
positive vessels associated with the number of lymph node metastasis (Po0.001). Furthermore, the presence of CD105-positive
vessels within the epithelial cell clusters associated with poor disease-free survival (P¼0.007).
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Cervical cancer is the second most common cancer among women
worldwide and one of the main causes of cancer-related death in
the developing countries (Parkin et al, 2005). The prognosis of
patients is, amongst others, dependent on tumour size, lymph
node metastasis, capillary lymphatic space involvement, infiltra-
tion of the tumour in the cervix, infiltration of the tumour in the
parametria and absence of tumour at the surgical margins
(Hellebrekers et al, 1999). Cervical tumours are composed of
malignant epithelial cells, tumour stroma, comprising the tumour
vasculature, and an inflammatory infiltrate. A significant associa-
tion between tumour vascular density and poor clinical outcome
has been reported (Cooper et al, 1998, 1999; Pilch et al, 2001a).
Growth and metastatic capacity of solid tumours depend on
tumour vascular density and angiogenesis (Pilch et al, 2001b;
Bremnes et al, 2006). Hypoxia in the centre of the epithelial cancer
cell nests is thought to be a driving force behind angiogenesis
(Byrne et al, 2005).
Tumours promote angiogenesis by secreting factors, like
vascular endothelial growth factor-A (VEGF-A), basic fibroblast
growth factor (bFGF) (Salgado et al, 2004; Bremnes et al, 2006) and
transforming growth factor (TGF)-b1. In addition, the presence of
an inflammatory infiltrate is thought to be of great importance in
neovascularisation (Condeelis and Pollard, 2006).
A marker for angiogenesis is endoglin (Dallas et al, 2008).
Endoglin, designated CD105, is a 90kDa (under reducing
conditions) TGF-b type III auxiliary receptor involved in the
regulation of TGF-b1 signalling in endothelial cells. Overexpression
of CD105 inhibits TGF-b/ALK5 signalling and TGF-b-induced
growth inhibition, whereas knockdown of CD105 inhibits TGF-b/
ALK1 signalling and endothelial cell proliferation (ten Dijke et al,
2008). CD105 is required for efficient TGF-b/ALK1 signalling on
proliferating endothelial cells (ten Dijke and Arthur, 2007). In
contrast to CD31, which is expressed on blood vessels both in
normal tissue and in malignant lesions, endoglin is found
predominantly on peritumoural and intratumoural blood vessels.
The expression of CD105 on tumour-associated blood vessels
makes CD105 a potential molecular target for therapy (Dallas et al,
2008).
Transforming growth factor-b1 plays a dual role in cancer: early
in tumour development it acts as a tumour suppressor, inhibiting
epithelial cell proliferation, whereas late in cancer development it
suppresses the activity of the immune system and induces
regulatory T cells (Elliott and Blobe, 2005). Transforming growth
factor-b1 also plays an important role in angiogenesis by
promoting proliferation and migration of endothelial cells at low
TGF-b1 concentrations, whereas high concentrations lead to
cytostasis and promote vessel maturation (ten Dijke and
Arthur, 2007). Furthermore, TGF-b1 is known to induce VEGF
expression (McMahon et al, 2006). Earlier we have reported on the
expression of TGF-b1, plasminogen activator inhibitor (PAI)-1 and
fibronectin (both target gene products of TGF-b1) and avb6
(activator of TGF-b1) in cervical carcinoma (Hazelbag et al, 2002,
2004, 2007).
In this study, we have expanded our observations on the role
of TGF-b1 in cervical cancer by measuring the number and
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sdetermining the location of CD105-positive blood vessels. To
further analyse the role of endoglin as a TGF-b1-associated
regulatory molecule in the angiogenic process, we have compared
the number and location of the newly formed CD105-positive
vessels with the number and location of CD31-positive blood
vessels (total number of blood vessels) and we have measured the
expression of the pro-angiogenic factors, VEGF-A and bFGF.
Finally, the clinico-pathological relevance of CD105 in cervical
carcinoma was assessed.
MATERIALS AND METHODS
Patient material
A total of 30 patients treated with radical abdominal hysterectomy
and bilateral pelvic lymph node dissection for uterine cervical
cancer (Wertheim’s procedure) was included in this study.
According to the International Federation of Gynaecology and
Obstetrics (FIGO) staging system for cervical carcinoma (Moore,
2006) 10 patients were selected for a high FIGO stage (at least FIGO
IIA), whereas the other 20 patients were randomly selected patients
with a FIGO stage IB. Patients had received no therapy before
surgery. Treatment occurred between 1985 and 1994. Tissues had
been fixed routinely in 10% v/v formalin and embedded in
paraffin. Samples were used according to the guidelines of the
Ethical Committee of the Leiden University Medical Centre. The
patient characteristics are shown in Table 1.
Immunohistochemistry
Immunohistochemical analysis was performed on 3mm paraffin
sections, mounted on aminopropylethoxysilane-coated slides.
Sections were deparaffinised, rehydrated and treated with 0.3%
v/v H2O2 in methanol for 20min to block endogenous peroxidase
activity. Antigen retrieval was performed, if necessary, and
sections were rinsed in phosphate-buffered saline (PBS) followed
by an incubation with 1% w/v bovine serum albumin (BSA) in PBS.
Subsequently, sections were stained for CD68 (Zijlmans et al,
2006), anb6 (Hazelbag et al, 2007), fibronectin (Hazelbag et al,
2002), VEGF-A, bFGF, matrix metalloproteinase (MMP)-2
(Sier et al, 2006), CD31 and CD105 (see Table 2 for characteristics
of the primary antibodies). All antibodies were diluted in 1% BSA
in PBS. In case of CD68, anb6, bFGF, MMP-2 and CD31 (a
biotinylated secondary rabbit anti-mouse antibody) was used
(1:200, DAKO, Glostrup, Denmark). For VEGF-A, biotinylated
swine anti-rabbit antibody, and for fibronectin, biotinylated rabbit
anti-goat antibody was used (both 1:400, DAKO). All slides were
subsequently incubated with a biotinylated horseradish peroxidase
(HRP)–streptavidin complex (1:100, DAKO) and immune com-
plexes were visualised with diaminobenzidine. Staining for CD105
was performed with a CSA Detection System (DAKO), according to
the manufacturer’s protocol. Negative controls consisting of tissue
sections where the primary antibody was replaced by an
(irrelevant) antibody (DAKO) directed against the same isotype
as the primary antibody.
Probe preparation and RNA-in situ hybridisation
Oligonucleotide primers were chosen on the basis of
known sequences (50-GCCTCCGAAACCATGAACTTT-30 (sense)
and 50-CCGCATAATCTGCATGGTGAT-30 (antisense)) (GenBank
accession number GI065522.1).
Cervical carcinoma sections were stained for VEGF-A mRNA as
described earlier (Zijlmans et al, 2006). In short: 3mm paraffin
sections were pre-treated and hybridised with 100ngml
 1 DIG-
labelled RNA probe diluted in hybridisation mixture containing
0.3 M NaCl and 0.03 M saline-sodium citrate (SSC). Hybridisation
was allowed for 16h at 501C in a humidified chamber. Slides were
washed for 30min in 50% v/v formamide/2  SSC at 421C,
followed by 45min in 0.1  SSC with 20mM b-mercaptoethanol at
501C and 30min with 2Uml
 1 ribonuclease (RNase) T1 (Roche
Diagnostics GmbH, Mannheim, Germany) in 2  SSC, 1mM EDTA
at 371C. RNA hybrids were detected using subsequently mouse
anti-digoxigenin (1:2000, Sigma-Aldrich Chemie GmbH, Steinham,
Germany), rabbit anti-mouse Ig (1:50, DAKO) and mouse alkaline
phosphatase anti-alkaline phosphatase (APAAP, DAKO). The
sense probe of each antisense VEGF-A mRNA probe served as a
Table 1 Summary of clinico-pathological features of patients and
tumours
Characteristics of patients and tumours Outcome N
a
Age 45 (mean) 30
29–72 (range)
FIGO stage pIB 20
XIIA 10
Lymph node metastasis No 16
Yes 14
Tumour size
b o40mm 16
X40mm 12
Infiltration depth
b o15mm 15
X15mm 9
Vascular space involvement No 10
Yes 20
Parametrial invasion No 20
Yes 10
HPV status
b 16, 18 19
Other 6
Histology Squamous 25
Adenosquamous 4
Adeno 1
FIGO¼Federation of Gynaecology and Obstetrics.
aN¼number of patients/cervical
carcinomas.
bCases missing.
Table 2 Characteristics of used primary antibodies
Antigen Clone Source Directed against
Antigen
retrieval Dilution
Incubation
conditions Manufacturer
anb6 2G2 Mouse b6 Citrate 0.01 M 1:2000 on 41C Biogen Idec, Cambridge, MA, USA
bFGF 6 Mouse bFGF Citrate 0.01 M 1:600 on 41C BD Biosciences, Franklin Lakes, NJ, USA
CD31 JC/70A Mouse Endothelial cells Citrate 0.01 M 1:400 on RT Neomarkers, Fremont, CA, USA
CD68 KP-1 Mouse Macrophages Trypsin 0.1% w/v 1:1600 on
a RT
b Dako, Glostrup, Denmark
CD105 SN6H Mouse Endoglin None 1:2000 1h RT Dako, Glostrup, Denmark
Fibronectin Goat Fibronectin Pepsin 0.4% w/v 1:1000 on RT Sigma, St Louis, MO, USA
MMP-2 CA-4001 Mouse Proform of MMP-2 None 1:200 on RT Neomarkers, Fremont, CA, USA
VEGF-A Rabbit VEGF-A Pepsin 0.4% w/v 1:100 2h RT Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA
bFGF¼basic fibroblast growth factor; VEGF¼vascular endothelial growth factor-A.
aOn¼overnight.
bRT¼room temperature.
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snegative control. A cervical cancer sample stained for TGF-b1
mRNA served as a positive control.
Evaluation of immunohistochemical staining and
RNA-in situ hybridisation
CD68-, VEGF- and bFGF-positive cells were quantitated by
counting the number of stained cells per five, randomly selected,
high-power fields (HPF,  400). CD68-positive cells at the border
of the epithelial–stromal interface were counted as present or
absent. CD31- and CD105-positive vessels were quantitated by first
searching for a high density of vessels at low magnification ( 200,
the so called ‘hot-spots’) in the stroma, followed by counting the
number of positive vessels in five of these hot-spots at high
magnification (HPF,  400) (Weidner et al, 1991). The presence of
CD105-positive vessels within the epithelial cell clusters or at the
epithelial–stroma interface, were counted as present or absent.
Fibronectin was scored at the epithelial–stroma interface as
described by Havenith et al (1988), dividing the immunoreactivity
in either o75% immunoreactivity or 475% immunoreactivity.
The staining of VEGF-A mRNA as well as VEGF-A protein, PAI-1,
MMP-2 and anb6 in the tumour cells was scored as described
earlier (Ruiter et al, 1998). Intensity was scored as none (0), weak
(1), moderate (2) or strong (3) at low magnification ( 100).
CD105 CD31
bFGF VEGF
VEGF RISH Control
a1 b1
d1
A B
C D
E F
Figure 1 Expression and location of CD105- and CD31-positive vessels, bFGF, VEGF fibronectin, avb6, PAI-1 and CD68-positive cells. Expression and
location of CD105- and CD31-positive vessels, bFGF and VEGF-A were determined using immunohistochemistry as well as RNA-in situ hybridisation as
described in Materials and Methods ( 125 magnification). (A) CD105 vascular staining, A1. Detail ( 400 magnification) of vessels present in the tumour
stroma as well as in the epithelial cell clusters, (B) CD31vascular staining, B1. Detail ( 400 magnification) of vessels present in the tumour stroma as well as
in the epithelial cell clusters. (C) bFGF, positive staining of the border of the epithelial cell clusters and cells in the stromal compartment; (D) VEGF-A
immunohistochemical staining with increased positive staining of the borders of the epithelial cell clusters, D1. Detail ( 400 magnification) of VEGF-A-
positive stromal cells, (E) VEGF-A RNA-in situ hybridisation with weak cytoplasmic staining of the epithelial cell clusters, (F) Negative (sense) control of VEGF-
A RNA-in situ hybridisation. Expression and location of fibronectin, avb6, PAI-1 and CD68-positive cells ( 400 magnification). (G) fibronectin, positive
staining (475%) of the stromal compartment. (H) avb6, positive staining (strong intensity; of the border) of the epithelial cell clusters. (I) PAI-1, positive
staining of the epithelial cell clusters. (J) Positive staining of CD68-positive cells in the stromal compartment and in the epithelial cell clusters.
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sFurthermore, the percentage of positive tumour cells was
determined and divided into groups, numbered from 0 to 5: 0%
(0, absent), 1–5% (1, sporadic), 6–25% (2, local), 26–50%
(3, occasional), 51–75% (4, majority) and 76–100% (5, large
majority). The two parameters were combined, representing the
sum of both the percentage and the staining intensity of the
positive cells, resulting in an overall score (0 or 2–8). Owing to low
expression of VEGF-A, the scores were combined into two groups:
category 0 (score 0, no expression), category 1 (score 2–8,
expression present). Expression was scored by two independent
researchers without knowing the identity and clinical outcome of
patients.
Statistical analysis
Data from immunohistochemistry as well as RNA-in situ
hybridisation are given as the mean±s.d. Statistical analysis was
performed using SPSS 14.0 (SPSS Inc., Chicago, IL, USA). Data
were processed by using a w
2-test, the Mann–Whitney U-test or
the Fisher’s exact test, depending on number and distribution of
the compared groups. Kaplan–Meier survival curves were
generated to assess differences in disease-free survival (defined
as the observation time in months from surgery to relapse of the
disease) or cumulative overall survival (defined as time in months
from surgery to death owing to cervical cancer). Po0.05 was
considered statistically significant.
RESULTS
Number and location of CD105- and CD31-positive blood
vessels
First, we have investigated the relationship between the number
and location of (newly formed) blood vessels, using anti-CD105
and anti-CD31 (providing an estimate of the total number of blood
vessels) monoclonal antibodies (Figure 1A and B, respectively).
The number of newly formed stromal CD105-positive vessels
(mean 5±1) was lower than the number of stromal CD31-positive
vessels (mean 9±1). The number of CD105-positive vessels ranged
from 0 to 20, whereas the number of CD31-positive vessels ranged
from 2 to 23. In 8 out of 30 cases CD105-positive vessels were
Fibronectin v6
PAI-1 CD68
G H
I J
Figure 1 Continued.
0 1 2 3 4 5
0
1
2
3
4
5
CD105-positive vessels (Sqrt N)
C
D
3
1
-
p
o
s
i
t
i
v
e
 
v
e
s
s
e
l
s
 
(
S
q
r
t
 
N
)
Figure 2 Correlation between CD105- and CD31-positive vessels.
Number of stromal CD105- and CD31-positive vessels was determined
using immunohistochemistry as described in Materials and Methods
(Pearson, r
2¼0.747, Po0.001).
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CD31-positive vessels were observed within these clusters. There
was a significant correlation between the expression of CD105- and
CD31-positive vessels in the stroma (r
2¼0.747, Po0.001; Figure 2).
Number and location of VEGF-A and bFGF-positive cells
Subsequently, we have investigated the number and location of
bFGF- and VEGF-A-positive cells (Figure 1C and D, respectively).
Basic fibroblast growth factor-positive cells were predominantly
observed in the stroma. The number of bFGF-positive cells ranged
from 0 to 71 (mean 24±5). Only 3 out of 30 cases showed bFGF
expression within the epithelial cell nests. These cells were mainly
located at the epithelial–stromal interface. Another six tumours
showed bFGF-positive cells within the necrotic centres of epithelial
nests, whereas tumour cells showed a negative staining. Vascular
endothelial growth factor-A was both measured at the protein level
using with immunohistochemistry and at the mRNA level using
RNA-in situ hybridisation (Figure 1E). Vascular endothelial
growth factor-A-positive cells were mainly observed in the stroma.
The number of VEGF-A-positive cells ranged from 0 to 77 (mean
11±3). Weak VEGF-A protein expression was observed through-
out the epithelial cell clusters with an increased intensity at the
epithelial–stromal interface (16 out of 30 cases; Figure 1D). In
addition, VEGF-A (mRNA) expression was observed in the
epithelial cell clusters (14 out of 30 cases). Expression of VEGF-A
(mRNA) within the epithelial cell clusters did not correlate with
VEGF-A protein expression within the epithelial cell clusters, but
did associate with the number of VEGF-A-positive cells in the
stroma (P¼0.048, Figure 3A).
Association between blood vessels and bFGF and VEGF-A
No significant association between the presence of CD105-positive
vessels in the tumour or the total number of CD105-positive and
CD31-positive vessels in the stroma, and the number of bFGF- or
VEGF-A-positive cells in the stroma was observed (data not
shown). However, both the number of CD105-positive and the
number of CD31-positive vessels in the stroma associated
significantly with expression of VEGF-A (mRNA) within the
epithelial cell clusters (P¼0.013 (Figure 3B) and P¼0.005
(Figure 3C), respectively).
Association between blood vessels and tumour-associated
macrophages
As angiogenic factors are also produced by tumour-associated
macrophage (TAM), we have enumerated the number of CD68-
positive cells (Zijlmans et al, 2007) and correlated their number
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Figure 3 Association between VEGF-A (mRNA) expression measured in the epithelial cell clusters and the number of VEGF-A-positive cells and blood
vessels. (A) Correlation between VEGF-A (mRNA) expression measured in the epithelial cell clusters and the number of VEGF-A-positive cells (Mann–
Whitney U-test, P¼0.048) in tumour stromal compartment. (B) Correlation between VEGF-A (mRNA) expression measured in the epithelial cell clusters
and the number of stromal CD105-positive vessels (Mann–Whitney U-test, P¼0.013). (C) Correlation between VEGF-A (mRNA) expression measured in
the epithelial cell clusters and the number of stromal CD31-positive vessels (Mann–Whitney U-test, P¼0.005).
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swith the number of CD105- and CD31-positive stromal vessels. The
presence of CD105-positive vessels in the tumour was significantly
associated with total (stroma and epithelial cell clusters) number of
CD68-positive cells (P¼0.004; Figure 4A). However, the number
of CD105-positive vessels in the stroma was not significantly
correlated with the total number of CD68-positive cells. In
addition, there was a significant correlation between the number
of CD31-positive vessels in the stroma and the total number of
CD68-positive cells (r
2¼0.150, P¼0.034; Figure 4B).
Association between blood vessels and TGF-b1 target gene
products PAI-1 and fibronectin and the TGF-b1 activator
anb6
To explore the role of TGF-b in the generation of CD105-positive
vessels both the presence of CD105-positive blood vessels in the
epithelial cell clusters and the number of blood vessels in the
stroma were associated with the presence of PAI-1 in the epithelial
cell clusters (Hazelbag et al, 2004) and the amount of fibronectin in
the stroma (Hazelbag et al, 2002), both target genes of TGF-b1.
Neither the presence of CD105-positive vessels within the epithelial
cell clusters nor the number of stromal CD105-positive vessels
associated significantly with PAI-1 expression (data not shown).
However, an association between the number of stromal CD31-
positive vessels and high levels of fibronectin (475%) was found
(P¼0.038; data not shown). Furthermore, a significant association
between the number of stromal CD31-positive vessels and
moderate or strong staining intensity (vs no or weak staining
intensity at the epithelial–stromal interface) of anb6 was observed
(P¼0.006; Figure 5B). Although a difference between the number
of stromal CD105-positive vessels and moderate or strong staining
intensity (vs no or weak staining intensity at the epithelial–stromal
interface) of anb6 was observed (Figure 5A), this difference was
not significant (P¼0.053). In addition, an association between the
total number of TAM and anb6 staining intensity was found
(P¼0.002; Figure 5C).
Association between blood vessels and clinico-pathological
parameters
Finally, we have associated both the presence of CD105-positive
blood vessels within the epithelial cell clusters and the number of
stromal CD105- or CD31-positive blood vessels with the FIGO
stage, lymph node metastasis, tumour size, infiltration depth,
vascular space involvement, parametrial invasion, human papillo-
mavirus (HPV) status and histology. No significant associations
were found between the majority of these parameters and the
presence of CD105-positive blood vessels within the epithelial cell
clusters or the number of stromal blood vessels. Only the presence
of CD31-positive vessels in the epithelial cell clusters associated
significantly with vascular space involvement (Fisher’s exact test,
P¼0.021).
The number of both CD105- and CD31-positive stromal vessels
was significantly associated with the presence of positive lymph
nodes (P¼0.005 and P¼0.011, respectively).
In addition, the number of CD105-positive stromal vessels was
significantly associated with the number of positive lymph nodes
(Po0.001; Figure 6A). Finally, the presence of CD105-positive
vessels within the epithelial cell clusters showed a negative
relationship with disease-free survival (Figure 6C; P¼0.007).
Sample size was too small to calculate whether or not this is an
independent prognostic variable.
DISCUSSION
In this study, we have investigated the role of endoglin (CD105), a
regulator of TGF-b signalling on endothelial cells, bFGF and
VEGF-A expression in 30 cervical carcinoma specimens. Most
vessels were detected in the stroma as could be expected, as a pre-
existing vascular network is necessary for developing new vessels
(Hicklin and Ellis, 2005). Only one recent study has reported on
the expression of CD105 in cervical cancer (Mazibrada et al, 2008).
In agreement with this study, we also observed a positive
correlation between the number of (newly formed) CD105- and
(total number) CD31-positive vessels. In addition, we observed
both CD105- and CD31-positive vessels within the epithelial cancer
cell clusters. As blood vessels originate from the vasculature in the
stroma, we assume that these vessels are embedded in thin layer of
stroma and surrounded by epithelial cancer cells.
Subsequently, we have assessed the association between the
number of CD105-vessels and bFGF- and VEGF-A expressing cells.
We did not observe an association between bFGF-expressing cells
with the number of CD105 (or CD31)-positive vessels. An increase
in bFGF mRNA expression has been reported during cervical
tumour development (Fujimoto et al, 1997; Van Trappen et al,
2002), whereas a decrease in bFGF expression was reported in the
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Figure 4 Association between tumour-associated macrophages and
blood vessels. (A) Association between the number of total (stroma and
epithelial cell clusters) tumour-associated macrophages and the presence of
CD105-positive vessels (Mann–Whitney U-test, P¼0.004). (B) Correla-
tion between the total number of tumour-associated macrophages and the
number of stromal CD31-positive vessels (Pearson, r
2¼0.150, P¼0.034).
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sstudy of Soufla et al (2005). To our knowledge, our study is the
first study on bFGF-expressing cells in cervical carcinoma at the
protein level using immunohistochemistry. Our study confirmed
the absence of a statistical significant association between bFGF
and VEGF-A expression in cervical cancer (data not shown) as
earlier shown by Van Trappen et al (2002) using PCR-analysis.
A negative association between VEGF-A protein expression and
microvessel density, was reported by Tjalma et al (2000) in a study
comprising 152 cervical carcinoma patients. In our study, we did
not find an association between either the number of CD105 (or
CD31)-positive vessels (microvessel density) and VEGF-A protein
expression. In contrast to the study of Tjalma et al (2000), in our
study we have also determined the presence of VEGF-A mRNA
expressing cells. We were able to show a positive association
between expression of VEGF-A mRNA and both CD105 expression
and CD31 expression, suggesting that expression of VEGF-A
mRNA is positively associated with microvessel density. The
associations remained significant even after a Bonferroni’s
correction for multiple testing by a factor 3. The presence of
VEGF-A mRNA only detectable in the centre of the epithelial cell
clusters, suggests that this is caused by hypoxia (Lee et al, 2008).
Although VEGF-A is considered to be one of the most important
factors involved in angiogenesis (Hicklin and Ellis, 2005),
surprisingly VEGF-A protein present at the epithelial–stromal
interface did not correlate with the number of CD105 (or CD31)-
positive vessels. This might be explained by consumption of
VEGF-A protein by target cells.
The role of TAM in pressing an angiogenic switch has been
highlighted by Lin and Pollard (2007), suggesting that TAM
significantly contribute to angiogenesis. Tumour-associated
macrophages are known to contain many proangiogenic factors,
such as VEGF (Leek et al, 2000), TNF-a (Pusztai et al, 1994),
CXCL-8 (Fujimoto et al, 2000), bFGF (Stupack et al, 1999) and
proteases such as MMP-2 and MMP-9 (Pollard, 2004). These
MMPs are able to free pro-angiogenic cytokines, such as TGF-b
and VEGF-A, from the matrix. Indeed, we could show a positive
association between the presence of CD105-positive vessels in the
tumour, the stromal number of CD31-positive vessels and the total
number of TAM. In contrast, an earlier study by Davidson et al
(1999), using CD31 as a vessel marker did not find this association.
Our results suggest that that the presence of TAM is associated
with neo-angiogenesis. However, there was no significant relation-
ship between the number of VEGF-A-positive cells in stroma or
VEGF-A protein in the epithelial cancer cell clusters and the
number of TAM. This suggests that other factors in addition to
VEGF-A contribute to angiogenesis. These factors may be induced
by cytokines from TAM or liberated from the extracellular matrix
by MMPs derived from TAM. In addition, we did not observe a
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Figure 5 Association between avb6 expression and CD31-positive vessels and tumour-associated macrophages. (A) Association between the presence
of moderate/strong avb6 intensity and the number of stromal CD105-positive vessels (Mann–Whitney U-test, P¼0.053). (B) Association between the
presence of moderate/strong avb6 intensity and the number of stromal CD31-positive vessels (Mann–Whitney U-test, P¼0.006). (C) Association
between the presence of moderate/strong avb6 intensity and the total number of tumour-associated macrophages (Mann–Whitney U-test, P¼0.002).
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between the epithelial cancer cells and VEGF-A protein (Sier et al,
2006).
Transforming growth factor-b1 plays an important role in
angiogenesis, by promoting proliferation and migration of
endothelial cells or promoting vessel maturation (ten Dijke and
Arthur, 2007). Furthermore, TGF-b1 is known to induce VEGF
expression (McMahon et al, 2006). We did not observe an
association between the presence or the number of CD105-positive
vessels and PAI-1, fibronectin (surrogate markers of TGF-b1
activity), anb6 and MMP-2 (activators of TGF-b1) expression.
However, the total number of (CD31-positive) vessels correlated
with the expression of anb6. In addition, anb6 correlated
significantly with the amount of fibronectin (P¼0.037, data not
shown), which is one of the factors that supports blood vessel
growth (Hazelbag et al, 2007). Interestingly, anb6 is also known to
upregulate MMP-9 expression and thus may also contribute to the
release of VEGF-A from the extracellular matrix (Scott et al, 2004).
On the basis of all our findings, we suggest that TGF-b1 also
plays a central role in the progression of cervical carcinoma
(Figure 7). Latent TGF-b1 is produced amongst others by cervical
cancer cells, secreted and stored in the extracellular matrix.
This TGF-b1 is then processed by either the epithelial cell
specific integrin anb6 (Sheppard, 2005; Hazelbag et al, 2007) or
by MMPs, especially active MMP-2 (Sier et al, 2006) in complex
with MMP-14 and TIMP-2 on the cell membrane of cervical cancer
cells at the epithelial cell–stroma border. Active TGF-b1 can
induce VEGF in the epithelial cancer cells and differentiates
fibroblasts surrounding the epithelial cancer cells into myofibro-
blasts. Furthermore, active TGF-b1 depending on the local
concentration either promotes endothelial proliferation and
migration or promotes cytostatis and vessel maturation. In
addition, active TGF-b1 acts as an immunosuppressor by blocking
the activity of the inflammatory cells and inducing FoxP3-positive
regulatory cells (Jordanova et al, 2008) and Th17 cells (Manel et al,
2008).
The prognostic value of CD105 and CD31 has been assessed
earlier in breast, colon and ovarian carcinomas (Dales et al, 2004;
Erdem et al, 2006; Minhajat et al, 2006; Dhakal et al, 2008). High
expression of CD105 correlated with increased risk of metastasis in
lymph node-positive breast carcinoma patients (Dales et al, 2004).
In this latter study, CD105 was shown to have an improved
predictive value compared with CD31. In agreement with this
study, in cervical carcinoma we observed an association between
the number of CD105-positive vessels and the number of positive
lymph nodes. With respect to survival, only the presence of newly
formed vessels (CD105) within the epithelial cell clusters was
correlated with a poor disease-free survival.
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Figure 6 Association between CD105-positive vessels, the number of positive lymph nodes and survival. (A) Correlation between the number of stromal
CD105 positive vessels and the number of positive lymph nodes (r
2¼0.615; Po0.001), (B) Overall survival (Kaplan–Meier, logrank 1.55, P¼0.214), (C).
Disease-free survival (Kaplan–Meier, logrank 7.28, P¼0.007), both stratified by presence of CD105-positive vessels within the epithelial cell clusters of
cervical carcinoma. K CD105 present in epithelial cell clusters, ’ CD105 absent in epithelial cell clusters.
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in the epithelial cell clusters may be of use as a (poor) prognostic
factor in cervical carcinoma. This is important as CD105 has been
proposed as a marker of tumour vasculature and a potential target
for therapy of cervical carcinoma (Dallas et al, 2008).
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